209 related articles for article (PubMed ID: 34534680)
21. Molecular Subtypes of High-Grade Neuroendocrine Carcinoma (HGNEC): What is YAP1-Positive HGNEC?
Kawai H; Matsuoka R; Ito T; Matsubara D
Front Biosci (Landmark Ed); 2022 Mar; 27(3):108. PubMed ID: 35345340
[TBL] [Abstract][Full Text] [Related]
22. Whole-Section Landscape Analysis of Molecular Subtypes in Curatively Resected Small Cell Lung Cancer: Clinicopathologic Features and Prognostic Significance.
Hwang S; Hong TH; Kim HK; Choi YS; Zo JI; Shim YM; Han J; Chan Ahn Y; Pyo H; Noh JM; Lee HY; Kim HJ; Park S; Ahn MJ; Park K; Lee SH; Choi YL; Kim J
Mod Pathol; 2023 Jul; 36(7):100184. PubMed ID: 37054974
[TBL] [Abstract][Full Text] [Related]
23. NEUROD1 is highly expressed in extensive-disease small cell lung cancer and promotes tumor cell migration.
Ikematsu Y; Tanaka K; Toyokawa G; Ijichi K; Ando N; Yoneshima Y; Iwama E; Inoue H; Tagawa T; Nakanishi Y; Okamoto I
Lung Cancer; 2020 Aug; 146():97-104. PubMed ID: 32526603
[TBL] [Abstract][Full Text] [Related]
24. BET Inhibitors Target the SCLC-N Subtype of Small-Cell Lung Cancer by Blocking NEUROD1 Transactivation.
Chen H; Gesumaria L; Park YK; Oliver TG; Singer DS; Ge K; Schrump DS
Mol Cancer Res; 2023 Feb; 21(2):91-101. PubMed ID: 36378541
[TBL] [Abstract][Full Text] [Related]
25. Clinical utility of immunohistochemical subtyping in patients with small cell lung cancer.
Chiang CL; Huang HC; Luo YH; Shen CI; Chao HS; Tseng YH; Chou TY; Schrump DS; Yeh YC; Chen YM
Lung Cancer; 2024 Feb; 188():107473. PubMed ID: 38232600
[TBL] [Abstract][Full Text] [Related]
26. POU domain transcription factor BRN2 is crucial for expression of ASCL1, ND1 and neuroendocrine marker molecules and cell growth in small cell lung cancer.
Ishii J; Sato H; Sakaeda M; Shishido-Hara Y; Hiramatsu C; Kamma H; Shimoyamada H; Fujiwara M; Endo T; Aoki I; Yazawa T
Pathol Int; 2013 Mar; 63(3):158-68. PubMed ID: 23530560
[TBL] [Abstract][Full Text] [Related]
27. POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer.
Huang YH; Klingbeil O; He XY; Wu XS; Arun G; Lu B; Somerville TDD; Milazzo JP; Wilkinson JE; Demerdash OE; Spector DL; Egeblad M; Shi J; Vakoc CR
Genes Dev; 2018 Jul; 32(13-14):915-928. PubMed ID: 29945888
[TBL] [Abstract][Full Text] [Related]
28. Molecular subtype expression and genomic profiling differ between surgically resected pure and combined small cell lung carcinoma.
Zhu Y; Li S; Wang H; Chi K; Ren W; Huang X; Zhuo M; Lin D
Hum Pathol; 2023 Nov; 141():118-129. PubMed ID: 37586462
[TBL] [Abstract][Full Text] [Related]
29. ASCL1 represses a SOX9
Olsen RR; Ireland AS; Kastner DW; Groves SM; Spainhower KB; Pozo K; Kelenis DP; Whitney CP; Guthrie MR; Wait SJ; Soltero D; Witt BL; Quaranta V; Johnson JE; Oliver TG
Genes Dev; 2021 Jun; 35(11-12):847-869. PubMed ID: 34016693
[TBL] [Abstract][Full Text] [Related]
30. Distinct transcriptional programs of SOX2 in different types of small cell lung cancers.
Tenjin Y; Matsuura K; Kudoh S; Usuki S; Yamada T; Matsuo A; Sato Y; Saito H; Fujino K; Wakimoto J; Ichimura T; Kohrogi H; Sakagami T; Niwa H; Ito T
Lab Invest; 2020 Dec; 100(12):1575-1588. PubMed ID: 32801334
[TBL] [Abstract][Full Text] [Related]
31. Comprehensive analysis of transcription factor-based molecular subtypes and their correlation to clinical outcomes in small-cell lung cancer.
Park S; Hong TH; Hwang S; Heeke S; Gay CM; Kim J; Jung HA; Sun JM; Ahn JS; Ahn MJ; Cho JH; Choi YS; Kim J; Shim YM; Kim HK; Byers LA; Heymach JV; Choi YL; Lee SH; Park K
EBioMedicine; 2024 Apr; 102():105062. PubMed ID: 38492534
[TBL] [Abstract][Full Text] [Related]
32. Promoters of ASCL1- and NEUROD1-dependent genes are specific targets of lurbinectedin in SCLC cells.
Costanzo F; Martínez Diez M; Santamaría Nuñez G; Díaz-Hernandéz JI; Genes Robles CM; Díez Pérez J; Compe E; Ricci R; Li TK; Coin F; Martínez Leal JF; Garrido-Martin EM; Egly JM
EMBO Mol Med; 2022 Apr; 14(4):e14841. PubMed ID: 35263037
[TBL] [Abstract][Full Text] [Related]
33. KDM6A epigenetically regulates subtype plasticity in small cell lung cancer.
Duplaquet L; Li Y; Booker MA; Xie Y; Olsen SN; Patel RA; Hong D; Hatton C; Denize T; Walton E; Laimon YN; Li R; Jiang Y; Bronson RT; Southard J; Li S; Signoretti S; Qiu X; Cejas P; Armstrong SA; Long HW; Tolstorukov MY; Haffner MC; Oser MG
Nat Cell Biol; 2023 Sep; 25(9):1346-1358. PubMed ID: 37591951
[TBL] [Abstract][Full Text] [Related]
34. Tumor-derived Vimentin as a novel biomarker for distinct subtypes predicting adjuvant chemotherapy resistance and T-cell-inflamed phenotype in small cell lung cancer.
Deng C; Wang Y; Fu F; Li D; Zheng Q; Jin Y; Li Y; Chen H; Zhang Y
MedComm (2020); 2023 Oct; 4(5):e370. PubMed ID: 37789961
[TBL] [Abstract][Full Text] [Related]
35. Ascl1-induced Wnt11 regulates neuroendocrine differentiation, cell proliferation, and E-cadherin expression in small-cell lung cancer and Wnt11 regulates small-cell lung cancer biology.
Tenjin Y; Kudoh S; Kubota S; Yamada T; Matsuo A; Sato Y; Ichimura T; Kohrogi H; Sashida G; Sakagami T; Ito T
Lab Invest; 2019 Nov; 99(11):1622-1635. PubMed ID: 31231131
[TBL] [Abstract][Full Text] [Related]
36. SCLC-CellMiner: A Resource for Small Cell Lung Cancer Cell Line Genomics and Pharmacology Based on Genomic Signatures.
Tlemsani C; Pongor L; Elloumi F; Girard L; Huffman KE; Roper N; Varma S; Luna A; Rajapakse VN; Sebastian R; Kohn KW; Krushkal J; Aladjem MI; Teicher BA; Meltzer PS; Reinhold WC; Minna JD; Thomas A; Pommier Y
Cell Rep; 2020 Oct; 33(3):108296. PubMed ID: 33086069
[TBL] [Abstract][Full Text] [Related]
37. In-depth proteomic analysis reveals unique subtype-specific signatures in human small-cell lung cancer.
Szeitz B; Megyesfalvi Z; Woldmar N; Valkó Z; Schwendenwein A; Bárány N; Paku S; László V; Kiss H; Bugyik E; Lang C; Szász AM; Pizzatti L; Bogos K; Hoda MA; Hoetzenecker K; Marko-Varga G; Horvatovich P; Döme B; Schelch K; Rezeli M
Clin Transl Med; 2022 Sep; 12(9):e1060. PubMed ID: 36149789
[TBL] [Abstract][Full Text] [Related]
38. Integrated Immunohistochemical Study on Small-Cell Carcinoma of the Lung Focusing on Transcription and Co-Transcription Factors.
Sato Y; Okamoto I; Kameyama H; Kudoh S; Saito H; Sanada M; Kudo N; Wakimoto J; Fujino K; Ikematsu Y; Tanaka K; Nishikawa A; Sakaguchi R; Ito T
Diagnostics (Basel); 2020 Nov; 10(11):. PubMed ID: 33202998
[TBL] [Abstract][Full Text] [Related]
39. Killing SCLC: insights into how to target a shapeshifting tumor.
Sutherland KD; Ireland AS; Oliver TG
Genes Dev; 2022 Mar; 36(5-6):241-258. PubMed ID: 35318269
[TBL] [Abstract][Full Text] [Related]
40. Does subtyping of high-grade pulmonary neuroendocrine carcinomas have an impact on therapy selection?
Popper H; Brcic L; Eidenhammer S
Transl Lung Cancer Res; 2023 Dec; 12(12):2412-2426. PubMed ID: 38205203
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
